Sai Life Sciences Ltd

Sai Life Sciences Ltd

Sai Life Sciences Ltd is hosting an earnings conference call on November 6, 2026, to discuss its unaudited financial results for the second quarter and half year ended September 30, 2026.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has allotted 54,500 equity shares under its Employees Stock Option Plan 2008, increasing its issued, subscribed, and paid-up equity share capital from ₹21,24,18,217 to ₹21,24,72,716.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026, stating that the details of securities dematerialized/rematerialized during the period have been furnished to all stock exchanges where the company's shares are listed.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 to consider and approve unaudited financial results for the second quarter and half year ended 30th September 2026.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has closed its trading window for dealing in securities for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the announcement of unaudited financial results for the second quarter and half year ending September 30, 2026.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced an investors conference on September 18, 2026, at Jefferies 5th India Forum in Gurgaon, where company officials will discuss publicly available information.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced an investors conference on September 14th, 2026, as part of the 24th Annual Global Healthcare Conference in New York. The meeting will be held in-person and will be based on publicly available information, with no unpublished price-sensitive information to be shared.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has allotted 80,600 equity shares under its Employees Stock Option Plan 2008 and Management Employee Stock Option Plan 2018, increasing its issued, subscribed, and paid-up equity share capital from ₹21,23,13,617 to ₹21,23,94,216.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has published a newspaper advertisement regarding the completion of dispatch of the Notice of the 27th Annual General Meeting (AGM) scheduled to be held on September 17, 2026, through video conference or other audio-visual means.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has sent web link letters to shareholders whose email addresses are not registered with the company, containing the navigation path to access the Integrated Annual Report for FY 2025-26.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has published its Business Responsibility and Sustainability Report (BRSR) and ESG Databook for FY 2025-26, as per Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced its Integrated Annual Report for FY 2025-26, which includes the Notice of the 27th AGM to be held on September 17, 2026. The report is available on the company's website and has been sent to members via email.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced its 27th Annual General Meeting (AGM) to be held on September 17, 2026, through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting will consider the audited standalone and consolidated financial statements for the year ended March 31, 2026, and the appointment of a director in place of Mr. Krishnamraju Kanumuri.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced that it will hold its 27th Annual General Meeting (AGM) on September 17, 2026, through video conference or other audio-visual means.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced the 27th Annual General Meeting (AGM) to be held on September 17, 2026, through video conferencing. The company has also set a cut-off date for e-voting on September 10, 2026.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced its Q1 FY27 earnings, with revenue growing by 12% year-over-year, driven by growth across two businesses, particularly in the CRO, which grew by 26% year-over-year. The company remains confident of its growth trajectory and prospects, with planned capacity expansion going live in the second half of the year.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 291.0 crore and total income from operations of Rs. 559.9 crore.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as per Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, detailing the utilization of proceeds from its Initial Public Offer (IPO).

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced the recording of its earnings call for the unaudited financial results for the quarter ended 30 June 2026. The call was held on 07 August 2026, and the recording is available on the company's website.

Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced its investor presentation for the quarter ended 30 June 2026, showcasing a 12% year-on-year growth in revenue to ₹554 crore, with a 15% increase in material margin and a 22% rise in PAT. The company has also highlighted its pipeline visibility, with over 90% of FY27 targets already visible. The presentation also mentions the company's progress in strengthening large pharma collaborations, expanding its top-tier pharma relationship, and operationalizing a new R&D facility.